- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Mary-Ellen Taplin discusses the significance of PSA nadir values in metastatic hormone-sensitive prostate cancer treatment, reviewing data from SWOG 9346 and CHAARTED trials that establish PSA nadir as a prognostic indicator while emphasizing that unfavorable PSA decline doesn't necessarily indicate progression. Biographies: Mary-E...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Gerhardt Attard discusses the future landscape of prostate cancer treatments and biomarkers, introducing STAMPEDE2's multi-arm trial design. Dr. Attard also addresses key challenges in radiographic progression-free survival measurements, patient selection, and treatment sequencing. Biographies: Gerhardt Attard, MD, PhD, FRCP, John...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Karim Fizazi leads a Q&A session exploring key questions in prostate cancer treatment de-escalation. The panel addresses practical considerations around re-imaging protocols and hormone therapy while highlighting the complexities of designing pragmatic trials that balance patient preferences with clinical outcomes, particularly reg...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Thomas Suter discusses the cardiovascular side effects of cancer therapies in prostate cancer patients. He emphasizes the importance of understanding how treatments like ADT impact cardiovascular health while outlining key recommendations from European Society of Cardiology guidelines. Biographies: Thomas Suter, MD, Professor, Bern...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Charles Ryan addresses the critical issue of cardiovascular toxicity in prostate cancer treatment, examining how ADT can increase cardiovascular event risk while exploring mechanisms like FSH elevation in plaque formation and the benefits of GnRH antagonists. The presentation discusses specific cardiac risks associated with differe...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Noel Clarke presents findings from the STAMPEDE trial regarding fracture risk and bone protection in prostate cancer patients. The presentation demonstrates that zoledronic acid reduces fracture incidence by about 50% in metastatic disease, and treatment intensification with abiraterone shows substantial fracture risk reduction, wh...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Lisa Horvath discusses the diagnosis and management of gynecomastia in prostate cancer patients undergoing ARPI therapy. The presentation compares preventive approaches, highlighting tamoxifen's superior prophylactic efficacy over radiotherapy, while noting surgery as the definitive treatment for established cases and emphasizing s...
|
